Carole B. Miller, MD, 
Siddharth Agrawal, MD, 
Lincoln Chang, MD 
St. Joseph’s University Medical Center, New Jersey, USA 

Denise Williams, MD, 

Jerald Radich, MD, 
Luke P. Akard, MD 
Dana Farber Cancer Institute, Boston, MA, USA

One patient reported nausea and dizziness (4%). Diarrhea was suspected to be related to nilotinib, and prophylaxis was not received in selected 2 patients.

Nilotinib was interrupted and the patient recovered from both events.

One patient discontinued the study due to AE due to AEs.

Five patients discontinued due to protocol defined non-CR according to the study criteria.

The median BCR-ABL log reduction for patients at the end of the study was 3.01 (0.015% IS; range, 2.88–3.56).

One of the 9 patients who were treated with nilotinib for at least 12 months (2/9) had a 1-log increase in BCR-ABL level at 12 months after the initiation of nilotinib (median, 3.01 log reduction; 0.015% IS; primary and per-protocol analyses).